| Literature DB >> 26965578 |
Peng Zhang1,2,3, Xingchao Wang1,2,3, Nan Ji1,2,3, Jian Xie1,2,3, Jinsong Han4, Xiaohui Ren1,2,3, Guidong Song1,2,3, Ruofei Wu1,2,3, Liwei Zhang1,2,3, Zhixian Gao5,6,7.
Abstract
BACKGROUND: Unilateral adult thalamic gliomas are rarely reported. In this study, the authors aimed to analyze the clinical, radiological, and pathological features of adult primary unilateral thalamus gliomas (UTGs).Entities:
Keywords: Gross total resection; Prognosis; Unilateral thalamic glioma
Mesh:
Year: 2016 PMID: 26965578 PMCID: PMC4785741 DOI: 10.1186/s12957-016-0820-x
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Parameters correlated with PFS and/or OS in 30 adult UTGs
| Characteristics | Median PFS (INR)a | Progression-free survival rates (%) |
| Median OS (INR)a | Overall survival rates (%) |
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 months | 12 months | 18 months | 24 months | 6 months | 12 months | 18 months | 24 months | |||||
| Age (years) | ||||||||||||
| <42 | N/A | 87.5 | 62.5 | 25.0 | 6.3 | <0.001 | N/A | 100.0 | 93.8 | 56.3 | 18.8 | <0.001 |
| ≥42 | N/A | 64.3 | 50.0 | 28.6 | 14.3 | N/A | 71.4 | 64.3 | 35.7 | 35.7 | ||
| Sex | ||||||||||||
| Male | N/A | 78.9 | 47.4 | 31.6 | 10.5 | 0.037 | N/A | 94.7 | 84.2 | 57.9 | 36.8 | <0.001 |
| Female | N/A | 72.7 | 72.7 | 18.2 | 9.1 | N/A | 72.7 | 72.7 | 27.3 | 9.1 | ||
| Lateral | ||||||||||||
| Left | N/A | 84.6 | 69.2 | 30.8 | 15.4 | <0.001 | N/A | 92.3 | 92.3 | 46.2 | 38.5 | <0.001 |
| Right | N/A | 70.6 | 47.1 | 23.5 | 5.9 | N/A | 82.4 | 70.6 | 47.1 | 17.6 | ||
| Preoperative kps | ||||||||||||
| ≥60 | N/A | 85.7 | 66.7 | 33.3 | 14.3 | <0.001 | N/A | 95.2 | 90.5 | 52.3 | 23.8 | <0.001 |
| <60 | 9(3–20) | 55.6 | 33.3 | 11.1 | 0.0 | N/A | 66.7 | 55.6 | 33.3 | 33.3 | ||
| Postoperative kps | ||||||||||||
| ≥60 | N/A | 84.0 | 72.0 | 36.0 | 16.0 | <0.001 | N/A | 92.0 | 84.0 | 52.0 | 40.0 | <0.001 |
| <60 | N/A | 40.0 | 20.0 | 0.0 | 0.0 | N/A | 60.0 | 60.0 | 20.0 | 20.0 | ||
| Symptom duration (months) | ||||||||||||
| ≥2 | N/A | 93.3 | 73.3 | 40.0 | 20.0 | <0.001 | N/A | 93.3 | 93.3 | 66.7 | 46.7 | <0.001 |
| <2 | 11(2–24) | 60.0 | 40.0 | 13.3 | 0.0 | N/A | 80.0 | 66.7 | 26.7 | 6.7 | ||
| Cystic changes | ||||||||||||
| Yes | N/A | 85.7 | 71.4 | 42.9 | 28.6 | <0.001 | N/A | 100.0 | 100.0 | 85.7 | 57.1 | <0.001 |
| No | N/A | 73.9 | 52.2 | 21.7 | 4.3 | N/A | 82.6 | 73.9 | 34.8 | 17.4 | ||
| Diameter (cm) | ||||||||||||
| <3.9 | N/A | 91.7 | 66.7 | 41.7 | 16.7 | <0.001 | N/A | 91.7 | 91.7 | 50.0 | 33.3 | <0.001 |
| ≥3.9 | N/A | 66.7 | 50.0 | 16.7 | 5.5 | N/A | 83.3 | 72.2 | 44.4 | 22.2 | ||
| Pathology | ||||||||||||
| Low grade | N/A | 100.0 | 100.0 | 50.0 | 25.0 | <0.001 | N/A | 100.0 | 100.0 | 75.0 | 50.0 | <0.001 |
| High grade | N/A | 68.2 | 40.9 | 18.2 | 4.5 | N/A | 81.8 | 72.7 | 36.4 | 18.2 | ||
| Postoperative v-p shunt | ||||||||||||
| Yes | 14.5(12–24) | 100.0 | 75.0 | 25.0 | 0.0 | – | N/A | 100.0 | 100.0 | 50.0 | 25.0 | <0.001 |
| No | N/A | 73.1 | 53.8 | 26.9 | 11.5 | N/A | 84.6 | 76.9 | 46.2 | 26.9 | ||
| Resection | ||||||||||||
| Gtr | N/A | 82.4 | 64.7 | 35.3 | 17.6 | <0.001 | N/A | 88.2 | 76.5 | 52.9 | 35.3 | <0.001 |
| Str/pr | 12(2–20) | 69.2 | 46.2 | 15.4 | 0.0 | N/A | 84.6 | 84.6 | 38.5 | 15.4 | ||
N/A not available
aMedian PFS and median OS was calculated based on the final status of follow-up
bMeans no correlation in univariate analysis
Clinical, radiological, and pathological features of 33 adult UTGs
| No. | Age (years) | Sex | Tumor location | Side | Diameter (cm) | Resection | Pathology | Postop therapy | Follow-up timea | Status at the last follow-up |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 53 | M | Th + Mid | Left | 3.8 | STR | A | Radio | 25.5 | Death with progression |
| 2 | 20 | F | Th + Mid | Right | 4.1 | PR | GBM | Radio | 21 | Death with progression |
| 3 | 20 | M | Th + IC | Right | 4.2 | STR | AA | Radio | 17 | Death with progression |
| 4 | 33 | M | Th + Mid | Right | 4.1 | GTR | OA | Radio | 24 | Death with progression |
| 5 | 32 | F | Th | Right | 3.1 | GTR | AA | Radio | 24 | Death with progression |
| 6 | 47 | F | Th + BG | Left | 3.5 | GTR | GBM | Radio | 30 | Death with progression |
| 7 | 38 | M | TH + Mid | Right | 3.4 | STR | AA | Radio | 14 | Death with progression |
| 8 | 37 | M | Th | Left | 3.9 | GTR | A | Radio | 24 | Death with progression |
| 9 | 56 | M | Th | Left | 1.2 | GTR | A | Radio | 46 | Alive without progression |
| 10 | 42 | M | Th | Right | 3.2 | GTR | GBM | Radio | 49 | Alive with progression |
| 11 | 21 | F | Th | Left | 4.5 | STR | AA | Radio | 17 | Death with progression |
| 12 | 37 | M | Th + IC | Left | 3.5 | GTR | GBM | Radio | 14 | Death with progression |
| 13 | 29 | M | Th + Mid + IC | Right | 4.1 | GTR | A | Radio | 35 | Death with progression |
| 14 | 46 | M | Th + IC | Left | 5.3 | GTR | GBM | – | 1 | Death without progression |
| 15 | 33 | M | Th + IC | Right | 6.2 | PR | GBM | – | – | Lost to follow-up |
| 16 | 29 | M | Th + IC + PiR | Right | 4.5 | GTR | OAb | Radio + chemo | 25 | Death with progression |
| 17 | 49 | F | Th | Right | 3.5 | GTR | AA | Radio | 17 | Death with progression |
| 18 | 48 | M | Th | Left | 4.2 | GTR | AOb | Radio + chemo | 27 | Death with progression |
| 19 | 36 | M | Th + IC + CTh | Right | 3.2 | PR | AOAb | Radio | 20 | Death without progression |
| 20 | 24 | M | Th + Mid + IC | Left | 5.4 | GTR | Ab | – | 14 | Alive without progression |
| 21 | 52 | F | Th + CTh | Right | 2.5 | STR | AOb | Radio + chemo | 2 | Death with progression |
| 22 | 21 | F | Th + Mid | Right | 3.8 | STR | AOAb | Radio + chemo | 12 | Alive without progression |
| 23 | 45 | F | Th + Mid | Right | 4.2 | GTR | GBMb | Radio + chemo | 3 | Death without progression |
| 24 | 30 | M | Th | Right | 3.9 | GTR | GBMb | Radio + chemo | 11 | Alive with progression |
| 25 | 43 | M | Th | Right | 4.7 | GTR | AAb | Radio + chemo | 11 | Alive without progression |
| 26 | 63 | F | Th + IC | Left | 4.1 | GTR | OAb | Chemo | 16 | Alive with progression |
| 27 | 47 | F | Th + BG + IC | Left | 3.4 | PR | GBMb | Radio + chemo | 4 | Alive without progression |
| 28 | 45 | F | Th + IC | Right | 4.8 | PR | GBMb | – | 3 | Death without progression |
| 29 | 20 | M | Th + Mid | Right | 5.3 | STR | AAb | Radio + chemo | 21 | Death with progression |
| 30 | 53 | F | Th + CTh | Left | 5.1 | GTR | OA | – | – | Lost to follow-up |
| 31 | 31 | M | Th + Mid + IC | Left | 5.2 | STR | AOAb | Radio | 24 | Death with progression |
| 32 | 66 | M | Th + Mid + IC | Right | 4.5 | GTR | GSM | Chemo | 1 week | Perioperative death |
| 33 | 48 | M | Th + Mid | Left | 5.2 | STR | GBMb | Radio + chemo | 13 | Death with progression |
Th thalamus, Mid midbrain, IC internal capsule, BG basal ganglia, PiR pineal region, CTh contralateral thalamus, GTR gross total resection (≥90 % resection), STR subtotal resection (≥80 but <90 %), PR partial resection (<80 %), A astrocytoma, AA anaplastic astrocytoma, AO anaplastic oligodendroglioma, AOA anaplastic oligodendroastrocytoma, GBM glioblastoma, GSM gliosarcoma, OA oligoastrocytoma
aThe follow-up time take the month as the unit
bThe molecular pathologies were available
Image features of 33 adult UTGs
| Characteristics | No. (%) of patients |
|---|---|
| Location of tumors | |
| Confined in the thalamus | 9 (27.3) |
| Extension to the brainstem | 12 (36.4) (including 4 extensions to the basal ganglia or internal capsule and 1 extension to the contralateral thalamus) |
| Extension to the contralateral thalamus | 3 (9.1) (including 1 extension to the brainstem and 1 extension to the internal capsule) |
| Extension to the basal ganglia and/or internal capsule | 14 (42.4) (including 4 extensions to the brainstem, 1 extension to the contralateral thalamus, and 1 extension to the habenular commissure) |
| Cystic changes | |
| Yes | 9 (27.3) |
| No | 24 (72.7) |
| T1 and T2 signals | |
| Hypointense T1 and hyperintense T2 | 14 (42.4) |
| Hypointense T1 and mixed T2 | 2 (6.1) |
| Mixed T1 and hyperintense T2 | 11 (33.3) |
| Mixed T1 and T2 | 6 (18.2) |
| Enhancement | |
| Yes | 30 (90.9) |
| No | 3 (9.1) |
Treatment details of 33 adult UTGs
| Characteristics | No. (%) of patients |
|---|---|
| Approaches | |
| Parieto-occipital transventriclular approach | 22(66.7) |
| Frontal transcortical approach | 6(18.2) |
| Precentral interhemispheric transcallosal interforniceal approach | 5(15.2) |
| Extent of surgical resection | |
| Gross total tumor resection (≥90 %) | 19 (57.6) |
| Subtotal tumor resection (≥80 but <90 %) | 9 (27.3) |
| Partial tumor resection (<80 %) | 5 (15.2) |
| Location of residual tumor | |
| Posterior part of the third ventricle | 3 (20)a |
| Lateral part of the thalamus adjacent to the internal capsule | 6 (40)a |
| Medial and internal part of the thalamus | 6 (40)a |
| Preoperative ventricular peritoneal shunt | |
| Yes | 7 (21.2) |
| No | 26 (78.8) |
| Postoperative ventricular peritoneal shunt | |
| Yes | 4 (12.1) |
| No | 29 (87.9) |
| Postoperative adjuvant therapy | |
| Radiotherapy + chemotherapy | 10 (30.3) |
| Radiotherapy | 16 (48.5) |
| Chemotherapy | 2 (6.1) |
aPercentage refers to the comparison reasons of the total residual tumor numbers of the patients (100 %)
Fig. 1Kaplan-Meier plots of PFS and OS for 30 UTGs patients
Molecular pathology features of 33 adult UTGs
| Molecular pathologies | UTGs no. (%) | Molecular pathologies | UTGs no.(%) | Molecular pathologies | UTGs no. (%) | |||
|---|---|---|---|---|---|---|---|---|
| P53 | TOPO-II | GST-π | ||||||
| + | 9(69.2) | + | 8(80) | + | 8(80) | |||
| − | 4(30.7) | − | 2(20) | − | 2(20) | |||
| GFAP | P-170 | PTEN | ||||||
| + | 10(90.9) | + | 5(50) | + | 9(100) | |||
| − | 1(9.1) | − | 5(50) | − | 0(0) | |||
| MGMT | Oligo-2 | EGFR | ||||||
| + | 6(60) | + | 9(100) | + | 6(66.7) | |||
| − | 4(40) | − | 0(0) | − | 3(33.3) | |||
| VEGF | MMP-9 | |||||||
| + | 6(60) | + | 9(90) | |||||
| − | 4(40) | − | 1(10) | |||||
Fig. 2Patients with low-grade pathology have longer PFS (a) and OS (b) than patients with high-grade. Gross total tumor resection is significantly associated with longer PFS (c) and OS (d)
Fig. 3Case 1. Cranial MRI examination revealed unilateral thalamus glioma located in the left thalamus and midbrain with hypointense T1 (a) and hyperintense T2 (b) signals, which were heterogeneously enhanced after injecting contrast agent (c–e). Postoperative MRI confirmed subtotal resection (f–j). Pathological examination revealed a diagnosis of astrocytoma (WHO Grade II). Original magnification ×100
Fig. 4Case 33. Cranial MRI examination revealed unilateral thalamus glioma located in the right thalamus and midbrain with mixed hypointense and hyperintense (a) and hyperintense T2 (b) signals with clear enhancement (c–e). Postoperative MRI confirmed subtotal resection (f–j). Original magnification ×100